Drug intelligence / Profile preview

azd6423

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Intravenous Infusion

Overview

AZD6423 is a small molecule drug developed by AstraZeneca as an antagonist of the N-methyl-D-aspartate (NMDA) receptor. It was investigated primarily for the treatment of suicidal ideation and potentially other central nervous system disorders. The mechanism of action involves antagonism at the NMDA receptor, which is implicated in glutamatergic neurotransmission and has been targeted for various neuropsychiatric conditions. Clinical development reached Phase 1 trials in healthy volunteers but was discontinued before further advancement[1][4][5][6].

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on azd6423.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azd6423.

Explore the full profile